Ann: Commercial Update and Regulatory Progress, page-109

Great articulation Chuk, I have been following the Opthea story with a view to taking a position once outcomes were known from the current phase 3 trials that have been running in parallel to each other and was stunned that the phase 3 trial data didn't reflect the outcomes of the initial phase 2 data. Disappointed more so for the potential patients that had a drug that had the initial potential to provide patients the chance of regaining some of their lost eyesight from AMD.

Relating this back to LTP, the Spontan product is derisked somewhat compared to the Opthea product as a result of it being a repurposed drug of something that has already been validated and approved only difference being it is now in a nasal delivery form compared to a tablet form.

I have been invested in LTP for some time and like a number of you commenting on this thread am also in the red and wasn't one of the fortunate ones to get in on the IPO, but still believe that this product has the potential to be a significant market disruptor in the ED treatment space once it finally does get it's different jurisdiction regulatory approvals.

I was also led to believe when I first invested that as the drug was already approved in a tablet form that the FDA approval process was going to be a walk in the park, but as Valueseek has noted in the BIO space when comparing it to the MSB journey, you don't really know the real timelines until you formally engage with the FDA and I think management probably underestimated the time lines re the approval process, not to mention the additional information and extra validation testing and associated costs that could be required to get the product over the line.

I too am looking forward to the webinar tomorrow and hope that it answers some of the unknowns that i have as well as others that have been raised here on this thread.